Urine Endocannabinoids As Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Apr 9

PMID 32260109

Citations 8

Authors

Riccardo Vago

Alessandro Ravelli

Arianna Bettiga

Silvana Casati

Giovanni Lavorgna

Fabio Benigni

Andrea Salonia

Francesco Montorsi

Marica Orioli

Pierangela Ciuffreda

Roberta Ottria

Affiliations

Soon will be listed here.

Abstract

Due to the involvement of the endocannabinoid system (ECS) in cancer onset and progression and the less studied connection between ECS and bladder cancer, here an evaluation of the ECS modifications associated with bladder cancer is reported. Urine samples were collected from healthy volunteers and patients with bladder cancer at different grades. Endocannabinoids (ECs) and N-acylethanolamides (NAEs) were quantified by HPLC-MS/MS and results normalized for creatinine content. An increase in the urine concentrations of four ECs and NAEs analyzed was observed with a statistically significant increase in the arachidonoylethanolamide (AEA) and stearoylethanoamide (SEA) associated with bladder cancer. Receiver operating characteristic curves built with AEA and SEA data allowed the selection of 160 pg/mL for SEA (area under the curve (AUC) = 0.91, Selectivity (SE) 94%, Specificity (SP) 45%) and 8 pg/mL for AEA (AUC = 0.85, SE 94%, SP 61%) as the best cut-off values. Moreover, data from bladder cancer samples at different grades were derived from The Cancer Genome Atlas, and the expressions of thirteen different components of the "endocannabinoidome" were analyzed. Statistical analysis highlights significant variations in the expression of three enzymes involved in EC and NAE turnover in bladder cancer.

Citing Articles

The Predictive Value of Plasma Bioactive Lipids on Craving in Human Volunteers With Alcohol Use Disorder.

Miliano C, Natividad L, Quello S, Stoolmiller M, Gregus A, Buczynski M Biol Psychiatry Glob Open Sci. 2024; 4(6):100368.

PMID: 39282655 PMC: 11400622. DOI: 10.1016/j.bpsgos.2024.100368.

Fluorescence-Based Enzyme Activity Assay: Ascertaining the Activity and Inhibition of Endocannabinoid Hydrolytic Enzymes.

Ciuffreda P, Xynomilakis O, Casati S, Ottria R Int J Mol Sci. 2024; 25(14).

PMID: 39062935 PMC: 11276806. DOI: 10.3390/ijms25147693.

2-Arachidonoylglycerol Synthesis: Facile and Handy Enzymatic Method That Allows to Avoid Isomerization.

Ottria R, Casati S, Rota P, Ciuffreda P Molecules. 2022; 27(16).

PMID: 36014430 PMC: 9416359. DOI: 10.3390/molecules27165190.

MALDI-TOF/MS Analysis of Non-Invasive Human Urine and Saliva Samples for the Identification of New Cancer Biomarkers.

Zambonin C, Aresta A Molecules. 2022; 27(6).

PMID: 35335287 PMC: 8951187. DOI: 10.3390/molecules27061925.

Components of the Endogenous Cannabinoid System as Potential Biomarkers for Interstitial Cystitis/Bladder Pain Syndrome.

Sultana S, Berger G, Lehmann C Diagnostics (Basel). 2022; 12(1).

PMID: 35054185 PMC: 8775086. DOI: 10.3390/diagnostics12010019.

References

Casati S, Manzocchi A, Ottria R, Ciuffreda P . 1H, 13C and 15N NMR spectral assignments of adenosine derivatives with different amino substituents at C6-position. Magn Reson Chem. 2011; 49(5):279-83. DOI: 10.1002/mrc.2736. View

Bettiga A, Aureli M, Colciago G, Murdica V, Moschini M, Luciano R . Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. Sci Rep. 2017; 7:42157. PMC: 5304189. DOI: 10.1038/srep42157. View

Vago R, Bettiga A, Salonia A, Ciuffreda P, Ottria R . Development of new inhibitors for N-acylethanolamine-hydrolyzing acid amidase as promising tool against bladder cancer. Bioorg Med Chem. 2017; 25(3):1242-1249. DOI: 10.1016/j.bmc.2016.12.042. View

Moreno E, Cavic M, Krivokuca A, Casado V, Canela E . The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?. Front Pharmacol. 2019; 10:339. PMC: 6459931. DOI: 10.3389/fphar.2019.00339. View

Hedlund P . Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn. 2013; 33(1):46-53. DOI: 10.1002/nau.22442. View

Carnovali M, Ottria R, Pasqualetti S, Banfi G, Ciuffreda P, Mariotti M . Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease. Pharmacol Res. 2015; 104:1-8. DOI: 10.1016/j.phrs.2015.12.009. View

Pezzilli R, Ciuffreda P, Ottria R, Ravelli A, Melzi dEril G, Barassi A . Serum endocannabinoids in assessing pain in patients with chronic pancreatitis and in those with pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2017; 52(10):1133-1139. DOI: 10.1080/00365521.2017.1342139. View

Hutter C, Zenklusen J . The Cancer Genome Atlas: Creating Lasting Value beyond Its Data. Cell. 2018; 173(2):283-285. DOI: 10.1016/j.cell.2018.03.042. View

Subiela J, Faba O, Guerrero Ramos F, Vila Reyes H, Pisano F, Breda A . Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes. Eur Urol Focus. 2019; 6(4):674-682. DOI: 10.1016/j.euf.2019.03.012. View

10.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

11.

Chanda D, Neumann D, Glatz J . The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target. Prostaglandins Leukot Essent Fatty Acids. 2018; 140:51-56. DOI: 10.1016/j.plefa.2018.11.016. View

12.

Fraguas-Sanchez A, Martin-Sabroso C, Torres-Suarez A . Insights into the effects of the endocannabinoid system in cancer: a review. Br J Pharmacol. 2018; 175(13):2566-2580. PMC: 6003657. DOI: 10.1111/bph.14331. View

13.

Bakali E, Elliott R, Taylor A, Willets J, Konje J, Tincello D . Distribution and function of the endocannabinoid system in the rat and human bladder. Int Urogynecol J. 2012; 24(5):855-63. DOI: 10.1007/s00192-012-1954-1. View

14.

Khan M, Sobocinska A, Czarnecka A, Krol M, Botta B, Szczylik C . The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. Curr Pharm Des. 2015; 22(12):1756-66. PMC: 5412000. DOI: 10.2174/1381612822666151211094901. View

15.

Ottria R, Casati S, Ciuffreda P . (1)H, (13)C and (15)N NMR assignments for N- and O-acylethanolamines, important family of naturally occurring bioactive lipid mediators. Magn Reson Chem. 2012; 50(12):823-8. DOI: 10.1002/mrc.3891. View

16.

Ottria R, Ravelli A, Gigli F, Ciuffreda P . Simultaneous ultra-high performance liquid chromathograpy-electrospray ionization-quadrupole-time of flight mass spectrometry quantification of endogenous anandamide and related N-acylethanolamides in bio-matrices. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 958:83-9. DOI: 10.1016/j.jchromb.2014.03.019. View

17.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

18.

Lauria S, Perrotta C, Casati S, Di Renzo I, Ottria R, Eberini I . Design, synthesis, molecular modelling and in vitro cytotoxicity analysis of novel carbamate derivatives as inhibitors of Monoacylglycerol lipase. Bioorg Med Chem. 2018; 26(9):2561-2572. DOI: 10.1016/j.bmc.2018.04.024. View

19.

Lu Y, Anderson H . Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017; 95(4):311-327. DOI: 10.1139/cjpp-2016-0346. View

20.

Gasperi V, Evangelista D, Oddi S, Florenzano F, Chiurchiu V, Avigliano L . Regulation of inflammation and proliferation of human bladder carcinoma cells by type-1 and type-2 cannabinoid receptors. Life Sci. 2014; 138:41-51. DOI: 10.1016/j.lfs.2014.09.031. View